Enhancing the Water Solubility and Efficacy of Anticancer Drugs Using Hydroxypropyl-β-Cyclodextrin

Area of Science:

• Pharmaceutical Sciences
• Drug Delivery
• Oncology

Background:

• Cyclodextrins (CyDs) are cyclic oligosaccharides forming inclusion complexes.
• Hydroxypropyl-β-cyclodextrin (HP-β-CyD) enhances solubility and biocompatibility of poorly water-soluble drugs.
• HP-β-CyD complexation can improve anticancer agent efficacy and selectivity.

Purpose of the Study:

• To explore the evolving role of HP-β-CyD in cancer therapy.
• To highlight HP-β-CyD's transition from formulation additive to active pharmaceutical ingredient.
• To discuss advanced drug delivery systems utilizing HP-β-CyD.

Main Methods:

• Review of existing literature on HP-β-CyD in drug formulation and cancer treatment.
• Analysis of studies demonstrating HP-β-CyD's impact on drug solubility, biocompatibility, and efficacy.
• Investigation of targeted delivery strategies, such as folate-conjugated HP-β-CyD.

Main Results:

• HP-β-CyD significantly improves the formulation properties of poorly water-soluble anticancer drugs.
• Complexation with HP-β-CyD can enhance the anticancer activity of various agents.
• HP-β-CyD shows direct therapeutic potential in leukemia and breast cancer treatment.
• Folate-conjugated HP-β-CyD demonstrates enhanced selectivity and potency against cancer cells, potentially involving autophagy.

Conclusions:

• HP-β-CyD is shifting from a formulation excipient to a key active pharmaceutical ingredient in oncology.
• Advanced drug delivery systems based on HP-β-CyD offer promising avenues for improved cancer therapy.
• The versatility of HP-β-CyD supports broader applications in developing novel anticancer treatments.